UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2006
Cholestech Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| California
|
|
000-20198
|
|
94-3065493 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
3347 Investment Boulevard
Hayward, California 94545
(Address of principal executive offices, including zip code)
(510) 732-7200
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition
On May 10, 2006, Cholestech Corporation (“Cholestech”) is issuing a press release and holding
a conference call regarding its financial results for the fourth quarter and fiscal year ended
March 31, 2006. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated by reference.
The information in this Current Report on Form 8-K and the exhibit attached hereto shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any
general incorporation language in such filing.
Use of Non-GAAP Financial Measures
To supplement its consolidated financial statements presented in accordance with GAAP,
Cholestech uses a non-GAAP measure, pro forma net income, which is adjusted from results based on
GAAP to exclude expenses incurred in connection with Cholestech’s transaction with Boule
Diagnostics International AB in November 2005. Further details about these charges can be found in
the press release.
Net
income excluding certain operating expenses is provided to enhance
investors’ overall
understanding of Cholestech’s operational performance, current financial performance and its
prospects for the future. Specifically, Cholestech believes this non-GAAP financial measure
provides useful information to both management and investors by excluding certain operating
expenses that Cholestech believes are not indicative of its core operating results. In addition,
since Cholestech has reported similar non-GAAP information to the investment community in the past,
Cholestech believes the inclusion of the non-GAAP financial measure provides consistency in its
financial reporting. Further, non-GAAP information allows for greater transparency to supplemental
information used by management in its financial and operational decision making. The presentation
of this additional information is not meant to be considered in isolation or as a substitute for
results prepared in accordance with accounting principles generally accepted in the United States.
The non-GAAP information Cholestech provides may be different from the non-GAAP information
provided by other companies.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Press Release of Cholestech Corporation dated May 10, 2006 |